HK1139861A1 - Pde7 inhibitors for use in the treatment of movement disorders 7(pde7) - Google Patents
Pde7 inhibitors for use in the treatment of movement disorders 7(pde7)Info
- Publication number
- HK1139861A1 HK1139861A1 HK10106488.4A HK10106488A HK1139861A1 HK 1139861 A1 HK1139861 A1 HK 1139861A1 HK 10106488 A HK10106488 A HK 10106488A HK 1139861 A1 HK1139861 A1 HK 1139861A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- pde7
- treatment
- movement disorders
- inhibitors
- pde7 inhibitors
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/433—Thidiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/527—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim spiro-condensed
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Neurology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Neurosurgery (AREA)
- Organic Chemistry (AREA)
- Psychology (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US92049607P | 2007-03-27 | 2007-03-27 | |
PCT/US2008/058530 WO2008119057A2 (fr) | 2007-03-27 | 2008-03-27 | Utilisation d'inhibiteurs pde7 dans le traitement des troubles du |
Publications (1)
Publication Number | Publication Date |
---|---|
HK1139861A1 true HK1139861A1 (en) | 2010-09-30 |
Family
ID=39789284
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HK10106488.4A HK1139861A1 (en) | 2007-03-27 | 2010-07-05 | Pde7 inhibitors for use in the treatment of movement disorders 7(pde7) |
Country Status (13)
Country | Link |
---|---|
US (3) | US20080260643A1 (fr) |
EP (1) | EP2139475B1 (fr) |
JP (2) | JP5580192B2 (fr) |
CN (2) | CN101917992A (fr) |
AU (1) | AU2008230710B2 (fr) |
BR (1) | BRPI0809244A2 (fr) |
CA (1) | CA2681650C (fr) |
ES (1) | ES2533206T3 (fr) |
HK (1) | HK1139861A1 (fr) |
MX (1) | MX2009010450A (fr) |
NZ (1) | NZ580413A (fr) |
RU (1) | RU2449790C2 (fr) |
WO (1) | WO2008119057A2 (fr) |
Families Citing this family (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8637528B2 (en) * | 2007-03-27 | 2014-01-28 | Omeros Corporation | Use of PDE7 inhibitors for the treatment of movement disorders |
CA2755768A1 (fr) * | 2009-03-23 | 2010-09-30 | Merck Sharp & Dohme Corp. | Antagonistes du recepteur p2x3 pour le traitement de la douleur |
FR2943673B1 (fr) * | 2009-03-27 | 2013-03-29 | Sanofi Aventis | Applications therapeutiques de derives de quinazolinedione |
FR2944282B1 (fr) | 2009-04-09 | 2013-05-03 | Sanofi Aventis | Derives de quinazolinedione, leur preparation et leurs diverses applications therapeutiques |
FR2944206B1 (fr) | 2009-04-09 | 2012-12-28 | Sanofi Aventis | Applications therapeutiques dans le domaine cardiovasculaire de derives de quinazolinedione |
AU2013202493B2 (en) * | 2009-05-04 | 2016-03-10 | Omeros Corporation | Use of PDE7 inhibitors for the treatment of movement disorders |
ES2353093B1 (es) * | 2009-05-20 | 2012-01-03 | Consejo Superior De Investigaciones Científicas (Csic) | Uso de derivados de quinazolinas y sus composiciones farmacéuticas en enfermedades neurodegenerativas. |
ES2360783B1 (es) | 2009-10-02 | 2012-07-04 | Consejo Superior De Investigaciones Científicas (Csic) | 1,2,4-tiadiazoles-5-imino sustituidos utiles en el tratamiento de enfermedades neurodegenerativas |
US9220715B2 (en) | 2010-11-08 | 2015-12-29 | Omeros Corporation | Treatment of addiction and impulse-control disorders using PDE7 inhibitors |
EP2640395A4 (fr) * | 2010-11-08 | 2014-01-22 | Omeros Corp | Traitement d'addiction et de troubles de contrôle des impulsions au moyen d'inhibiteurs de la pde7 |
JP2015521177A (ja) * | 2012-05-07 | 2015-07-27 | オメロス コーポレーション | Pde7インヒビターを用いる嗜癖および衝動制御障害の処置 |
DK2846805T3 (en) * | 2012-05-07 | 2019-03-18 | Omeros Corp | TREATMENT OF DEPENDENCE AND IMPULSE CONTROL DISORDERS USING PDE7 INHIBITORS |
EP3505171A4 (fr) * | 2016-08-26 | 2020-08-26 | Mitsubishi Tanabe Pharma Corporation | Composé hétérocyclique azoté bicyclique |
US20210330736A1 (en) * | 2018-09-05 | 2021-10-28 | Universiteit Van Amsterdam | Use of a pde11 or pde2 inhibitor for the treatment of parkinson's disease |
WO2024038090A1 (fr) | 2022-08-18 | 2024-02-22 | Mitodicure Gmbh | Utilisation de composés de benzofurane et de benzoxazole substitués pour le traitement et la prévention de maladies associées à la fatigue chronique, à l'épuisement et/ou à l'intolérance à l'effort |
Family Cites Families (68)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5453566A (en) | 1986-03-28 | 1995-09-26 | Calgene, Inc. | Antisense regulation of gene expression in plant/cells |
US4987071A (en) | 1986-12-03 | 1991-01-22 | University Patents, Inc. | RNA ribozyme polymerases, dephosphorylases, restriction endoribonucleases and methods |
ATE115999T1 (de) | 1987-12-15 | 1995-01-15 | Gene Shears Pty Ltd | Ribozyme. |
GB8822492D0 (en) | 1988-09-24 | 1988-10-26 | Considine J | Apparatus for removing tumours from hollow organs of body |
US5789573A (en) | 1990-08-14 | 1998-08-04 | Isis Pharmaceuticals, Inc. | Antisense inhibition of ICAM-1, E-selectin, and CMV IE1/IE2 |
IL108367A0 (en) | 1993-01-27 | 1994-04-12 | Hektoen Inst For Medical Resea | Antisense polynzcleotide inhibition of human growth factor-sensitive cancer cells |
US5801154A (en) | 1993-10-18 | 1998-09-01 | Isis Pharmaceuticals, Inc. | Antisense oligonucleotide modulation of multidrug resistance-associated protein |
US5739119A (en) | 1996-11-15 | 1998-04-14 | Galli; Rachel L. | Antisense oligonucleotides specific for the muscarinic type 2 acetylcholine receptor MRNA |
US5932465A (en) * | 1997-10-16 | 1999-08-03 | Icos Corporation | Phosphodiesterase 8A |
CA2321224A1 (fr) * | 1998-02-23 | 1999-08-26 | Icos Corporation | Phosphodiesterase 10 |
ATE371740T1 (de) * | 1998-12-23 | 2007-09-15 | Pfizer | Phosphodiesterasen |
WO2000068230A1 (fr) | 1999-05-05 | 2000-11-16 | Darwin Discovery Limited | Derives de 9-(1,2,3,4-tetrahydronapththalene-1-yle)-1,9-dihydropurine-6-un inhibiteurs de pde7 |
CA2373073A1 (fr) | 1999-05-07 | 2000-11-16 | Takeda Chemical Industries, Ltd. | Composes cycliques et leurs utilisations |
US6146876A (en) | 1999-06-11 | 2000-11-14 | Millennium Pharmaceuticals, Inc. | 22025, a novel human cyclic nucleotide phosphodiesterase |
US7491742B2 (en) * | 1999-10-21 | 2009-02-17 | Merck Patent Gmbh | Imidazole derivatives as phosphodiesterase VII inhibitors |
DE19950647A1 (de) | 1999-10-21 | 2001-04-26 | Merck Patent Gmbh | Imidazolderivate als Phosphodiesterase VII-Hemmer |
DE19953025A1 (de) * | 1999-11-04 | 2001-05-10 | Merck Patent Gmbh | Pyrrolderivate als Phosphodiesterase VII-Hemmer |
DE19953024A1 (de) * | 1999-11-04 | 2001-05-10 | Merck Patent Gmbh | Isoxazolderivate als Phosphodiesterase VII-Hemmer |
DE19953414A1 (de) * | 1999-11-06 | 2001-05-10 | Merck Patent Gmbh | Imidazopyridinderivate als Phospodiesterase VII-Hemmer |
DE19954707A1 (de) * | 1999-11-13 | 2001-05-17 | Merck Patent Gmbh | Imidazolverbindungen als Phosphodiesterase VII-Hemmer |
US6649592B1 (en) | 2000-01-14 | 2003-11-18 | Science & Technology Corporation @ Unm | Peptide inhibitors of LFA-1/ICAM-1 interaction |
WO2001062290A2 (fr) * | 2000-02-22 | 2001-08-30 | Cellegy Canada Inc. | Methodes et compositions destinees a ameliorer la qualite du sommeil |
WO2001062904A1 (fr) | 2000-02-24 | 2001-08-30 | Bayer Aktiengesellschaft | Regulation de l'enzyme 1 du type b-gelatinase humaine |
GB0007934D0 (en) | 2000-03-31 | 2000-05-17 | Darwin Discovery Ltd | Chemical compounds |
US7345031B2 (en) * | 2000-04-12 | 2008-03-18 | International Medical Innovations, Inc. | Pharmaceutical dopamine glycoconjugate compositions and methods of their preparation and use |
GB0015095D0 (en) | 2000-06-20 | 2000-08-09 | Celltech Chiroscience Ltd | Chemical compounds |
CN1471397A (zh) | 2000-08-30 | 2004-01-28 | 利利艾科斯有限公司 | 治疗偏头痛的方法 |
EP1193261A1 (fr) * | 2000-10-02 | 2002-04-03 | Warner-Lambert Company | Thiadiazoles et leur utilisation comme inhibiteurs de phophodiestérase-7 |
WO2002040449A1 (fr) | 2000-11-14 | 2002-05-23 | Altana Pharma Ag | Dihydroisoquinolines comme nouveaux inhibiteurs de phosphodiesterase |
US6818651B2 (en) * | 2000-11-14 | 2004-11-16 | Altana Pharma Ag | (Dihydro) isoquinoline derivatives as phosphodiesterase inhibitors |
IL140844A0 (en) * | 2001-01-10 | 2002-02-10 | Polygene Ltd | Cationic polysaccharide compositions |
EP1370211A4 (fr) * | 2001-03-02 | 2005-02-09 | Bristol Myers Squibb Co | Co-administration de l'agoniste du recepteur de la melanocortine et inhibiteur de phosphodiesterase pour le traitement de troubles associes a l'amp cyclique |
US6617357B2 (en) * | 2001-03-06 | 2003-09-09 | Smithkline Beecham Corporation | Compounds and their use as PDE inhibitors |
AP1699A (en) * | 2001-03-21 | 2006-12-26 | Warner Lambert Co | New spirotricyclic derivatives and their use as phosphodiesterase-7 inhibitors |
WO2002085894A1 (fr) | 2001-04-18 | 2002-10-31 | Ortho-Mcneil Pharmaceutical, Inc. | Arylindenopyridines presentant une activite d'inhibition des pde |
US6903109B2 (en) * | 2001-04-18 | 2005-06-07 | Ortho-Muniel Pharmaceutical, Inc. | Arylindenopyridines and related therapeutic and prophylactic methods |
US6958328B2 (en) | 2001-04-18 | 2005-10-25 | Ortho-Mcneil Pharmaceutical, Inc | Arylindenopyridines and related therapeutic and prophylactic methods |
US20030032579A1 (en) * | 2001-04-20 | 2003-02-13 | Pfizer Inc. | Therapeutic use of selective PDE10 inhibitors |
AU2002317733B2 (en) * | 2001-04-25 | 2007-12-13 | Altana Pharma Ag | Phthalazinones derivatives useful as PDE4/7 inhibitors |
CN100343258C (zh) | 2001-04-30 | 2007-10-17 | 美国拜尔公司 | 新的4-氨基-5,6-取代的噻吩并[2,3-d]嘧啶化合物 |
US20030053980A1 (en) | 2001-04-30 | 2003-03-20 | The Gillette Company | Shaving compositions containing highly lubricious water soluble polymers |
WO2002088079A2 (fr) | 2001-05-01 | 2002-11-07 | Bristol-Myers Squibb Company | Inhibiteurs doubles de pde 7 et pde 4 |
MXPA03011629A (es) * | 2001-06-15 | 2004-07-01 | Yamanouchi Pharmaceuticals Co | Derivado de fenilpiridincarbonilpiperazina. |
PE20030008A1 (es) * | 2001-06-19 | 2003-01-22 | Bristol Myers Squibb Co | Inhibidores duales de pde 7 y pde 4 |
JP2005500294A (ja) | 2001-06-19 | 2005-01-06 | ブリストル−マイヤーズ スクイブ カンパニー | ホスホジエステラーゼ7に対するピリミジン阻害剤 |
DE10130167A1 (de) | 2001-06-22 | 2003-01-02 | Bayer Ag | Imidazotriazine |
WO2003020702A2 (fr) * | 2001-08-31 | 2003-03-13 | The Rockefeller University | Activite de phosphodiesterase et regulation de la signalisation a mediation par phosphodiesterase 1-b dans le cerveau |
US20060286622A1 (en) * | 2001-09-28 | 2006-12-21 | Patricia Soulard | Polypeptides exhibiting PDE7 activity and their use for selecting compounds which inhibit PDE 7 enzyme activity |
WO2003053975A1 (fr) * | 2001-12-13 | 2003-07-03 | Daiichi Suntory Pharma Co., Ltd. | Derives de pyrazolopyrimidinone possedant une activite inhibitrice de pde7 |
DE10163991A1 (de) * | 2001-12-24 | 2003-07-03 | Merck Patent Gmbh | Pyrrolo-pyrimidine |
AU2002360774A1 (en) | 2001-12-28 | 2003-07-24 | Bayer Corporation | 4-substituted fused heteropyrimidines and fused hetero-4-pyrimidones |
TW200302726A (en) | 2002-01-31 | 2003-08-16 | Ono Pharmaceutical Co | Nitrogen-containing bicyclic compound and medicament containing same as active ingredient |
US20040082061A1 (en) * | 2002-02-14 | 2004-04-29 | Anna Astromoff | Drug metabolizing enzymes |
EP1348701A1 (fr) | 2002-03-28 | 2003-10-01 | Warner-Lambert Company LLC | Thiazol-5-yl-amines 2,4-disubstituées comme inhibiteurs de la PDE7 |
EP1348433A1 (fr) * | 2002-03-28 | 2003-10-01 | Warner-Lambert Company LLC | Thiazol-2-yl-imines comme inhibiteurs de la PDE7 |
EP1400244A1 (fr) | 2002-09-17 | 2004-03-24 | Warner-Lambert Company LLC | Nouveaux quinazolinones spirocondensés et leur utilisation comme inhibiteurs de la phosphodiesterase |
WO2004044196A1 (fr) | 2002-11-13 | 2004-05-27 | Bayer Healthcare Ag | Procedes de diagnostic de maladies associees a la phosphodiesterase 7b (pde7b) humaine et moyens therapeutiques correspondants |
ES2217956B1 (es) * | 2003-01-23 | 2006-04-01 | Almirall Prodesfarma, S.A. | Nuevos derivados de 4-aminotieno(2,3-d)pirimidin-6-carbonitrilo. |
US7217527B2 (en) * | 2003-04-15 | 2007-05-15 | Vanderbilt University | Assay for phosphodiesterase function |
JP2006219373A (ja) * | 2003-06-13 | 2006-08-24 | Daiichi Asubio Pharma Co Ltd | Pde7阻害作用を有するピリジニルピラゾロピリミジノン誘導体 |
JP2006219374A (ja) | 2003-06-13 | 2006-08-24 | Daiichi Asubio Pharma Co Ltd | Pde7阻害作用を有するイミダゾトリアジノン誘導体 |
US20050130971A1 (en) * | 2003-08-22 | 2005-06-16 | Pharmacia Corporation | Compositions of a cyclooxygenase-2 selective inhibitor and phosphodiesterase inhibitor for the treatment of ischemic mediated central nervous system disorders or injury |
CA2569530C (fr) | 2004-07-01 | 2013-07-30 | Daiichi Asubio Pharma Co.,Ltd. | Derive de thienopyrazole ayant une activite d'inhibition de la pde 7 |
WO2006092692A1 (fr) | 2005-03-01 | 2006-09-08 | Pfizer Limited | Utilisation d'associations d’inhibiteurs de pde7 et de ligands alpha-2-delta pour le traitement de la douleur neuropathique |
MX2007010721A (es) * | 2005-03-01 | 2007-11-13 | Pfizer Ltd | Nuevo uso de inhibidores de fosfodiesterasa 7 para el tratamiento de dolor neuropatico. |
EP1940389A2 (fr) * | 2005-10-21 | 2008-07-09 | Braincells, Inc. | Modulation de la neurogenese par inhibition de la pde |
RS20080233A (en) * | 2005-12-02 | 2009-07-15 | Pfizer Limited, | Spirocyclic quinazoline derivatives as pde7 inhibitors |
US8637528B2 (en) * | 2007-03-27 | 2014-01-28 | Omeros Corporation | Use of PDE7 inhibitors for the treatment of movement disorders |
-
2008
- 2008-03-27 MX MX2009010450A patent/MX2009010450A/es active IP Right Grant
- 2008-03-27 BR BRPI0809244-3A patent/BRPI0809244A2/pt not_active Application Discontinuation
- 2008-03-27 NZ NZ580413A patent/NZ580413A/xx unknown
- 2008-03-27 RU RU2009138966/15A patent/RU2449790C2/ru active
- 2008-03-27 WO PCT/US2008/058530 patent/WO2008119057A2/fr active Application Filing
- 2008-03-27 ES ES08744515.1T patent/ES2533206T3/es active Active
- 2008-03-27 EP EP08744515.1A patent/EP2139475B1/fr active Active
- 2008-03-27 JP JP2010501232A patent/JP5580192B2/ja active Active
- 2008-03-27 US US12/057,368 patent/US20080260643A1/en not_active Abandoned
- 2008-03-27 CN CN200880017058XA patent/CN101917992A/zh active Pending
- 2008-03-27 CN CN201510082785.6A patent/CN104758291B/zh active Active
- 2008-03-27 CA CA2681650A patent/CA2681650C/fr active Active
- 2008-03-27 AU AU2008230710A patent/AU2008230710B2/en active Active
-
2010
- 2010-07-05 HK HK10106488.4A patent/HK1139861A1/xx unknown
- 2010-12-21 US US12/974,693 patent/US20110091388A1/en not_active Abandoned
-
2014
- 2014-05-28 JP JP2014109910A patent/JP5943964B2/ja active Active
-
2018
- 2018-12-06 US US16/212,064 patent/US20190183824A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
WO2008119057A2 (fr) | 2008-10-02 |
CN101917992A (zh) | 2010-12-15 |
AU2008230710B2 (en) | 2014-04-10 |
CA2681650A1 (fr) | 2008-10-02 |
JP2014198718A (ja) | 2014-10-23 |
EP2139475A2 (fr) | 2010-01-06 |
CN104758291A (zh) | 2015-07-08 |
BRPI0809244A2 (pt) | 2014-09-23 |
CA2681650C (fr) | 2016-11-22 |
MX2009010450A (es) | 2009-11-23 |
RU2449790C2 (ru) | 2012-05-10 |
WO2008119057A3 (fr) | 2008-11-20 |
CN104758291B (zh) | 2020-03-03 |
NZ580413A (en) | 2012-11-30 |
US20190183824A1 (en) | 2019-06-20 |
RU2009138966A (ru) | 2011-05-10 |
AU2008230710A1 (en) | 2008-10-02 |
US20110091388A1 (en) | 2011-04-21 |
US20080260643A1 (en) | 2008-10-23 |
EP2139475B1 (fr) | 2014-12-17 |
ES2533206T3 (es) | 2015-04-08 |
JP5943964B2 (ja) | 2016-07-05 |
JP2010522768A (ja) | 2010-07-08 |
JP5580192B2 (ja) | 2014-08-27 |
EP2139475A4 (fr) | 2012-03-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1139861A1 (en) | Pde7 inhibitors for use in the treatment of movement disorders 7(pde7) | |
HRP20181608T1 (hr) | Korištenje inhibitora pde7 u liječenju bolesti kretanja | |
IL185485A0 (en) | Use of pde7 inhibitors for the treatment of neuropathic pain | |
GB2453188B (en) | Use of compounds in the manufacture of medicaments for treatment of regional fat deposits | |
EP1874286A4 (fr) | Methodes et compositions pour le traitement de troubles anxieux | |
IL193936A0 (en) | Compositions and methods for the treatment of immunoinflammatory disorders | |
IL195152A (en) | Compounds for use in treating diseases of cell culture | |
IL195906A0 (en) | Alpha-aminoamide derivatives useful in the treatment of cognitive disorders | |
HK1129426A1 (zh) | 用於治療肺部病症的酶的合成物 | |
EP1996218A4 (fr) | Méthodes et compositions servant au traitement de troubles gastro-intestinaux | |
IL205578A0 (en) | Aldh-2 inhibitors in the treatment of psychiatric disorders | |
ZA200806455B (en) | Use of 2-imidazoles for the treatment of CNS disorders | |
PT2054045E (pt) | Utilização de derivados de 2,5-di-hidroxibenzeno para o tratamento da artrite e da dor | |
IL188390A0 (en) | Imidazolyl-pyrimidine compounds for use in the treatment of proliferative disorders | |
EP2077838A4 (fr) | Procedes pour le traitement de troubles en rapport avec a , et compositions pour ceux-ci | |
HK1134032A1 (en) | New combination for use in the treatment of inflammatory disorders | |
IL192877A0 (en) | Use of 2-imidazoles for the treatment of cns disorders | |
IL192933A0 (en) | Benzoisoindole derivatives for the treatment of pain | |
EP2007790A4 (fr) | Composes et procedes destines au traitement de la douleur | |
GB0620695D0 (en) | Composition and methods for the treatment of nurdegenerative disease | |
IL193943A0 (en) | The use of beta- aminoalcohols for the treatment of inflammatory disorders and pain | |
GB0710277D0 (en) | Use of antivirals in the treatment of medical disorders | |
EP2370087A4 (fr) | Méthodes et compositions pour le traitement de troubles de rétention de fluide | |
ZA200707147B (en) | Use of PDE7 inhibitors for the treatment of neuropathic pain | |
IL193944A0 (en) | The use beta-aminoalcohols for the treatment of inflammatory disorders and pain |